Introduction: The pandemic of SARS CoV-2 has required urgent medical treatments for numerous patients. As no specific antiviral agents were available, different off-the-shelf alternatives have been explored.
Objective: Here, we review the rationale behind the use of Favipiravir, and report of the specific studies supporting this treatment being conducted.
Methods: Here we analyze the relevant literature to conclude about the present opportunities offered by this therapeutic agent.
Results: This antiviral drug approved influenza in Japan since 2014, has a demonstrated in vitro activity against SARS CoV-2 and is being investigated in several trials for SARS CoV-2. Signals of benefit were shown in a small trial for SARS CoV-2. However, in another small study, there was no advantage.
Conclusions: Further studies, statistically more significant, are urgently needed to understand the best opportunities offered by this treatment.
Keywords: Animal studies; Favipiravir; Human trials; Laboratory experiments; SARS CoV-2.